<DOC>
	<DOCNO>NCT02734810</DOCNO>
	<brief_summary>Liprotamase consist 3 soluble , non-porcine digestive enzyme , lipase , protease , amylase , combine fix ratio . Liprotamase stable stomach formulate without enteric coat administration either capsule dose solution dissolve water juice . The purpose present study provide efficacy safety data new , soluble formulation liprotamase , Liprotamase Powder Oral Solution , Cystic Fibrosis patient exocrine pancreatic insufficiency ( EPI ) .</brief_summary>
	<brief_title>SIMPLICITY : Studying Impacts Malabsorption With Liprotamase Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>For Part A : male females â‰¥7 year age For Part B : male females 28 day &lt; 7 year Diagnosis cystic fibrosis base presentation , genotype and/or sweat chloride Low fecal elastase Fairtogood nutritional status History diagnosis fibrosing colonopathy Distal intestinal obstruction syndrome 6 month prior screen Receiving enteral tube feeding Chronic diarrheal illness unrelated pancreatic insufficiency Liver abnormality , liver lung transplant , significant bowel resection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Liprotamase</keyword>
	<keyword>Pancreatic Enzyme Replacement Therapy ( PERT )</keyword>
</DOC>